Advaxia Biologics

Executive Summary

Advaxia Biologics is a private Italian contract development and manufacturing organization (CDMO) founded in 2018 and headquartered in Milan, specializing in adenovirus-based biologics and vaccines. The company offers fully integrated services from process development to cGMP manufacturing for viral vector products, leveraging its expertise to support clients in the immunology and oncology sectors. Advaxia has demonstrated a strong track record, having partnered with major pharmaceutical companies on vaccine development for Ebola and COVID-19, underscoring its capability to deliver high-quality biologics under tight timelines. As a CDMO, Advaxia benefits from the growing demand for viral vector manufacturing, driven by the expansion of gene therapies and vaccine platforms. The company is well-positioned to capitalize on this trend, though its private status and lack of disclosed financials limit visibility into its operational scale and margins. Overall, Advaxia represents a specialized service provider in a niche but rapidly growing segment of the biopharmaceutical industry.